Acute myocardial infarction: Development and application of an ICD-10-CM-based algorithm to a large U.S. healthcare claims-based database.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 25 08 2020
accepted: 08 06 2021
entrez: 1 7 2021
pubmed: 2 7 2021
medline: 18 11 2021
Statut: epublish

Résumé

Healthcare administrative claims data hold value for monitoring drug safety and assessing drug effectiveness. The U.S. Food and Drug Administration Biologics Effectiveness and Safety Initiative (BEST) is expanding its analytical capacity by developing claims-based definitions-referred to as algorithms-for populations and outcomes of interest. Acute myocardial infarction (AMI) was of interest due to its potential association with select biologics and the lack of an externally validated International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) algorithm. Develop and apply an ICD-10-CM-based algorithm in a U.S. administrative claims database to identify and characterize AMI populations. A comprehensive literature review was conducted to identify validated AMI algorithms. Building on prior published methodology and consistent application of ICD-9-CM codes, an ICD-10-CM algorithm was developed via forward-backward mapping using General Equivalence Mappings and refined with clinical input. An AMI population was then identified in the IBM® MarketScan® Research Databases and characterized using descriptive statistics. Between 2014-2017, 2.83-3.16 individuals/1,000 enrollees/year received ≥1 AMI diagnosis in any healthcare setting. The 2015 transition to ICD-10-CM did not result in a substantial change in the proportion of patients identified. Average patient age at first AMI diagnosis was 64.9 years, and 61.4% of individuals were male. Unspecified chest pain, hypertension, and coronary atherosclerosis of native coronary vessel/artery were most commonly reported within one day of AMI diagnosis. Electrocardiograms were the most common medical procedure and beta-blockers were the most commonly ordered cardiac medication in the one day before to 14 days following AMI diagnosis. The mean length of inpatient stay was 5.6 days (median 3 days; standard deviation 7.9 days). Findings from this ICD-10-CM-based AMI study were internally consistent with ICD-9-CM-based findings and externally consistent with ICD-9-CM-based studies, suggesting that this algorithm is ready for validation in future studies.

Sections du résumé

BACKGROUND
Healthcare administrative claims data hold value for monitoring drug safety and assessing drug effectiveness. The U.S. Food and Drug Administration Biologics Effectiveness and Safety Initiative (BEST) is expanding its analytical capacity by developing claims-based definitions-referred to as algorithms-for populations and outcomes of interest. Acute myocardial infarction (AMI) was of interest due to its potential association with select biologics and the lack of an externally validated International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) algorithm.
OBJECTIVE
Develop and apply an ICD-10-CM-based algorithm in a U.S. administrative claims database to identify and characterize AMI populations.
METHODS
A comprehensive literature review was conducted to identify validated AMI algorithms. Building on prior published methodology and consistent application of ICD-9-CM codes, an ICD-10-CM algorithm was developed via forward-backward mapping using General Equivalence Mappings and refined with clinical input. An AMI population was then identified in the IBM® MarketScan® Research Databases and characterized using descriptive statistics.
RESULTS AND DISCUSSION
Between 2014-2017, 2.83-3.16 individuals/1,000 enrollees/year received ≥1 AMI diagnosis in any healthcare setting. The 2015 transition to ICD-10-CM did not result in a substantial change in the proportion of patients identified. Average patient age at first AMI diagnosis was 64.9 years, and 61.4% of individuals were male. Unspecified chest pain, hypertension, and coronary atherosclerosis of native coronary vessel/artery were most commonly reported within one day of AMI diagnosis. Electrocardiograms were the most common medical procedure and beta-blockers were the most commonly ordered cardiac medication in the one day before to 14 days following AMI diagnosis. The mean length of inpatient stay was 5.6 days (median 3 days; standard deviation 7.9 days). Findings from this ICD-10-CM-based AMI study were internally consistent with ICD-9-CM-based findings and externally consistent with ICD-9-CM-based studies, suggesting that this algorithm is ready for validation in future studies.

Identifiants

pubmed: 34197488
doi: 10.1371/journal.pone.0253580
pii: PONE-D-20-26703
pmc: PMC8248590
doi:

Substances chimiques

Biological Products 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0253580

Subventions

Organisme : FDA HHS
Pays : United States

Déclaration de conflit d'intérêts

Several co-authors hold commercial affiliations with Gevity Consulting Inc. (PSH, SWH, JS) and IBM Watson Health (TB), and have delivered clinical and epidemiology consulting engagement for public and private sector partners. These affiliations did not impact the study design, data collection and analysis, decision to publish, or preparation of the manuscript, and do not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Eur J Cardiovasc Prev Rehabil. 2005 Apr;12(2):132-7
pubmed: 15785298
J Am Coll Cardiol. 2013 Jan 29;61(4):485-510
pubmed: 23256913
Neth Heart J. 2018 Jan;26(1):13-20
pubmed: 29119544
Epidemiol Prev. 2019 Jul-Aug;43(4 Suppl 2):37-50
pubmed: 31650805
Pharmacoepidemiol Drug Saf. 2020 Jul;29(7):770-777
pubmed: 31854053
Dtsch Arztebl Int. 2011 Dec;108(50):856-62
pubmed: 22259640
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:100-28
pubmed: 22262598
BMJ Open. 2016 Nov 18;6(11):e012832
pubmed: 27864249
Am J Cardiol. 2008 Feb 15;101(4):428-34
pubmed: 18312752
Medicine (Baltimore). 2016 Aug;95(32):e4554
pubmed: 27512881
J Cardiovasc Med (Hagerstown). 2012 Mar;13(3):194-202
pubmed: 22317927
J Clin Epidemiol. 2002 Nov;55(11):1082-7
pubmed: 12507671
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:154-62
pubmed: 22262602
Diabetes Care. 2018 Jan;41(1):39-48
pubmed: 29122893
Pharmacoepidemiol Drug Saf. 2018 Apr;27(4):398-404
pubmed: 29446185
Am Heart J. 2002 Aug;144(2):290-6
pubmed: 12177647
Sci Rep. 2019 Jan 31;9(1):1101
pubmed: 30705337
BMC Health Serv Res. 2018 Nov 26;18(1):895
pubmed: 30477501
BMC Public Health. 2018 Jan 19;18(1):161
pubmed: 29351744
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
JAMA Cardiol. 2018 Apr 1;3(4):336-340
pubmed: 29541764
Int J Angiol. 2013 Jun;22(2):115-22
pubmed: 24436595
Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):40-54
pubmed: 22745038
Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):596-603
pubmed: 20140892
BMJ Open. 2013 Jun 20;3(6):
pubmed: 23794587
CMAJ Open. 2015 Oct 02;3(4):E413-8
pubmed: 27570759
Circulation. 2004 May 4;109(17):2068-73
pubmed: 15096449
Circ Cardiovasc Qual Outcomes. 2017 Dec;10(12):e003443
pubmed: 29246884
EGEMS (Wash DC). 2014 Jan 14;1(3):1023
pubmed: 25848582
J Intern Med. 1997 Jun;241(6):485-92
pubmed: 10497624
Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):839-847
pubmed: 29947033
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:274-81
pubmed: 22262617
JAMA. 2014 Nov 19;312(19):1999-2007
pubmed: 25399275
PLoS One. 2014 Mar 28;9(3):e92286
pubmed: 24682186
Circulation. 2020 Feb 18;141(7):509-519
pubmed: 32065770

Auteurs

Patrick Saunders-Hastings (P)

Gevity Consulting Inc., Ottawa, ON, Canada.

Sze Wing Heong (SW)

Gevity Consulting Inc., Ottawa, ON, Canada.

Jenny Srichaikul (J)

Gevity Consulting Inc., Ottawa, ON, Canada.

Hui-Lee Wong (HL)

Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States of America.

Azadeh Shoaibi (A)

Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States of America.

Kinnera Chada (K)

Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States of America.

Timothy A Burrell (TA)

IBM Watson Health, Cambridge, MA, United States of America.

Graça M Dores (GM)

Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH